Entrada Therapeutics Capital Expenditures Over Time

TRDA Stock  USD 19.89  0.06  0.30%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Entrada Therapeutics Performance and Entrada Therapeutics Correlation.
For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.
  
As of December 1, 2024, Capital Expenditures is expected to decline to about 3.5 M.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.44
Revenue Per Share
6.074
Quarterly Revenue Growth
(0.55)
Return On Assets
0.0695
Return On Equity
0.1642
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Capital Expenditures Analysis

Compare Entrada Therapeutics and related stocks such as Molecular Partners, Pmv Pharmaceuticals, and Monte Rosa Therapeutics Capital Expenditures Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
MOLN1.5 M1.5 M1.5 M1.5 M546.1 K1.4 M1.1 M500 K867 K1.9 M1.7 M1.3 M1.4 M808 K1.3 M
PMVP452 K452 K452 K452 K452 K452 K452 K452 K452 K109 K148 K1.3 MM962 K913.9 K
GLUE1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M3.4 M9.7 M12.9 M19 M10.2 M
VIGL500 K500 K500 K500 K500 K500 K500 K500 K500 K500 K500 K204 K921 K674 K632.2 K
THRD36 K36 K36 K36 K36 K36 K36 K36 K36 K36 K36 K36 K36 K169 K177.4 K
CGEM0.00.00.00.00.00.00.0261 K261 K20 K10 K589.2 K1.1 M208 K222.1 K
EWTX180 K180 K180 K180 K180 K180 K180 K180 K180 K180 K203 K668 K5.5 M5.7 MM
RLYB188 K188 K188 K188 K188 K188 K188 K188 K188 K188 K137 K333 K54 K12 K11.4 K
CRNX190 K190 K190 K190 K190 K190 K190 K304 K1.1 M492 K186 K436 K1.7 M4.7 M4.9 M
CNTA186 K186 K186 K186 K186 K186 K186 K186 K186 K186 K186 K186 K1.1 M169 K160.6 K
IRON22 K22 K22 K22 K22 K22 K22 K22 K22 K22 K22 K68 K151 K89 K90.8 K
LRMR58 K58 K58 K58 K58 K595 K660 K55 K108 K83 K62 K333 K100 K164 K177.4 K
PEPG29 K29 K29 K29 K29 K29 K29 K29 K29 K29 KK500 K3.8 M2.6 M1.5 M
TYRA20 K20 K20 K20 K20 K20 K20 K20 K20 K20 K312 K661 K559 K770 K510.8 K
PHVS13.5 K13.5 K13.5 K13.5 K13.5 K13.5 K13.5 K13.5 K13.5 K13.5 K43 K130 K124.3 K90 K75.9 K
GNTA20.9 K20.9 K20.9 K20.9 K20.9 K20.9 K20.9 K20.9 K20.9 K20.9 K20.9 KK27.1 K13.8 K14.7 K
OPT0.039.9 K2.5 K111.1 K0.08.8 K2.4 K25.3 K8.8 KK17 K23.3 K32.6 K33.5 K31.8 K

Entrada Therapeutics and related stocks such as Molecular Partners, Pmv Pharmaceuticals, and Monte Rosa Therapeutics Capital Expenditures description

Capital Expenditures are funds used by Entrada Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Entrada Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

My Equities

My Current Equities and Potential Positions

Entrada Therapeutics
TRDA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationMassachusetts; U.S.A
ExchangeNASDAQ Exchange
USD 19.89
When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:
Check out Entrada Therapeutics Performance and Entrada Therapeutics Correlation.
For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Entrada Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Entrada Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Entrada Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...